{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:39:02Z","timestamp":1793039942122,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with migraine have an increased relative risk of cardio- and cerebrovascular events, and some migraine treatments may exacerbate this risk. The primary objective of this analysis was to determine whether the rate of cardiovascular adverse events was higher for patients with migraine treated with the migraine-preventive eptinezumab, compared with patients receiving placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cardiovascular outcomes in patients with migraine were pooled across four clinical trials (phase 1b, phase 2, and two phase 3 trials) for use of eptinezumab as a preventive migraine treatment for up to 1\u2009year. In all studies, treatment-emergent adverse events (TEAEs) that occurred after the first dose of study treatment (eptinezumab 100\u2009mg, 300\u2009mg, 1000\u2009mg, or placebo) and vital signs were recorded through study completion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cardiovascular TEAEs were rare across all four clinical trials, and rates were similar between patients receiving eptinezumab and those receiving placebo. Cardiovascular TEAEs that did occur were mild or moderate in severity; there were no serious adverse events as per FDA definition. Vital signs (systolic blood pressure, diastolic blood pressure, and heart rate) were not meaningfully different across treatment groups over the course of 56\u2009weeks, compared to placebo. Treatment with eptinezumab did not result in significant new or changed cardiovascular medications used concomitantly compared to placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this post hoc analysis of four clinical trials for eptinezumab, doses of 100\u2009mg, 300\u2009mg, and 1000\u2009mg (more than 3 times the highest approved dose) were not associated with clinically relevant changes in vital signs or significant changes in concomitant cardiovascular medication usage, and had low incidences of cardiovascular TEAEs, comparable to placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01772524\">NCT01772524<\/jats:ext-link> (Study 2), 01\/21\/2013; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02275117\">NCT02275117<\/jats:ext-link> (Study 5), 10\/27\/2014; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02559895\">NCT02559895<\/jats:ext-link> (PROMISE-1), 09\/25\/2017; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974153\">NCT02974153<\/jats:ext-link> (PROMISE-2), 11\/28\/2016<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-021-01360-1","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:32:03Z","timestamp":1638297123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies"],"prefix":"10.1186","volume":"22","author":[{"given":"Timothy R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egilius L. H.","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"11","key":"1360_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"GBD","year":"2016","unstructured":"GBD (2016) Headache collaborators (2018) global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17(11):954\u2013976. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"issue":"3","key":"1360_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27","author":"L Stovner","year":"2007","unstructured":"Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner TJ, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3):193\u2013210. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01288.x","journal-title":"Cephalalgia"},{"issue":"3","key":"1360_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020498","volume":"8","author":"AN Mahmoud","year":"2018","unstructured":"Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, Mohsen A, Abuzaid A, Mansoor H, Mojadidi MK, Elgendy IY (2018) Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 8(3):e020498. https:\/\/doi.org\/10.1136\/bmjopen-2017-020498","journal-title":"BMJ Open"},{"issue":"10","key":"1360_CR4","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1526-4610.2007.00937.x","volume":"47","author":"C Becker","year":"2007","unstructured":"Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR (2007) Migraine and the risk of stroke, TIA, or death in the UK (CME). Headache 47(10):1374\u20131384. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00937.x","journal-title":"Headache"},{"issue":"1","key":"1360_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1468-2982.2007.01469.x","volume":"28","author":"C Becker","year":"2008","unstructured":"Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR (2008) Migraine incidence, comorbidity and health resource utilization in the UK. Cephalalgia 28(1):57\u201364. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01469.x","journal-title":"Cephalalgia"},{"key":"1360_CR6","doi-asserted-by":"publisher","first-page":"i2610","DOI":"10.1136\/bmj.i2610","volume":"353","author":"T Kurth","year":"2016","unstructured":"Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JAE, Rexrode KM (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 353:i2610. https:\/\/doi.org\/10.1136\/bmj.i2610","journal-title":"BMJ"},{"issue":"22","key":"1360_CR7","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.2020.7172","volume":"323","author":"T Kurth","year":"2020","unstructured":"Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE (2020) Association of migraine with aura and other risk factors with incident cardiovascular disease in women. JAMA 323(22):2281\u20132289. https:\/\/doi.org\/10.1001\/jama.2020.7172","journal-title":"JAMA"},{"issue":"10","key":"1360_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573\u2013582. https:\/\/doi.org\/10.1038\/nrneurol.2010.127","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"1360_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1360_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/1523-1747.ep12455620","volume":"87","author":"SD Brain","year":"1986","unstructured":"Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ (1986) Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 87(4):533\u2013536. https:\/\/doi.org\/10.1111\/1523-1747.ep12455620","journal-title":"J Invest Dermatol"},{"key":"1360_CR11","volume-title":"package insert","author":"AIMOVIG","year":"2020","unstructured":"AIMOVIG (2020) package insert. Amgen Inc., Thousand Oaks"},{"key":"1360_CR12","volume-title":"package insert","author":"NURTEC ODT","year":"2021","unstructured":"NURTEC ODT (2021) package insert. Biohaven Pharmaceuticals, Inc., New Haven"},{"key":"1360_CR13","volume-title":"package insert","author":"UBRELVY","year":"2021","unstructured":"UBRELVY (2021) package insert. Allergan USA, Inc., Madison"},{"key":"1360_CR14","volume-title":"package insert","author":"QULIPTA","year":"2021","unstructured":"QULIPTA (2021) package insert. Ireland AbbVie, Dublin"},{"issue":"2","key":"1360_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.lfs.2014.02.024","volume":"118","author":"S Homma","year":"2014","unstructured":"Homma S, Kimura T, Sakai S, K-i Y, Miyauchi Y, Aonuma K et al (2014) Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: Intravital microscopic observation and 31P-MR spectroscopic studies. Life Sci 118(2):248\u2013254. https:\/\/doi.org\/10.1016\/j.lfs.2014.02.024","journal-title":"Life Sci"},{"issue":"4","key":"1360_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","volume":"88","author":"IA Mulder","year":"2020","unstructured":"Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K et al (2020) Anti-migraine calcitonin gene\u2013related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 88(4):771\u2013784. https:\/\/doi.org\/10.1002\/ana.25831","journal-title":"Ann Neurol"},{"issue":"5","key":"1360_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/01.fjc.0000159639.59770.36","volume":"45","author":"A Wackenfors","year":"2005","unstructured":"Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsj\u00f6 M (2005) Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol 45(5):476\u2013484. https:\/\/doi.org\/10.1097\/01.fjc.0000159639.59770.36","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"1360_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD (2019) Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39(11):1455\u20131464. https:\/\/doi.org\/10.1177\/0333102419854082","journal-title":"Cephalalgia"},{"issue":"1","key":"1360_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/head.13684","volume":"60","author":"TM Oakes","year":"2020","unstructured":"Oakes TM, Kovacs R, Rosen N, Doty E, Kemmer P, Aurora SK, Camporeale A (2020) Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache 60(1):110\u2013123. https:\/\/doi.org\/10.1111\/head.13684","journal-title":"Headache"},{"issue":"6","key":"1360_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R (2019) Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache 59(6):880\u2013890. https:\/\/doi.org\/10.1111\/head.13534","journal-title":"Headache"},{"issue":"1","key":"1360_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","volume":"374","author":"LF Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez LF, Raport CJ, Ojala EW, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham JA (2020) Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. JPET 374(1):93\u2013103. https:\/\/doi.org\/10.1124\/jpet.119.264671","journal-title":"JPET"},{"issue":"11","key":"1360_CR22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/s1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, ALD403 study investigators (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100\u20131107. https:\/\/doi.org\/10.1016\/s1474-4422(14)70209-1","journal-title":"Lancet Neurol"},{"issue":"9","key":"1360_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J (2019) Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39(9):1075\u20131085. https:\/\/doi.org\/10.1177\/0333102419858355","journal-title":"Cephalalgia"},{"issue":"3","key":"1360_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"13","key":"1360_CR25","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"10","key":"1360_CR26","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S (2020) Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache 60(10):2220\u20132231. https:\/\/doi.org\/10.1111\/head.14007","journal-title":"Headache"},{"issue":"1","key":"1360_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"issue":"1","key":"1360_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-021-01227-5","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22(1):16. https:\/\/doi.org\/10.1186\/s10194-021-01227-5","journal-title":"J Headache Pain"},{"issue":"8","key":"1360_CR29","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/cir.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW, On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee (2021) Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 143(8):e254\u2013e743. https:\/\/doi.org\/10.1161\/cir.0000000000000950","journal-title":"Circulation"},{"issue":"1","key":"1360_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E et al (2017) Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 18(1):96. https:\/\/doi.org\/10.1186\/s10194-017-0807-1","journal-title":"J Headache Pain"},{"issue":"S1","key":"1360_CR31","first-page":"123","volume":"61","author":"M Ashina","year":"2021","unstructured":"Ashina M, McAllister P, Cady R, Hirman J, Ettrup A (2021) Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: post hoc analysis PROMISE-1 and PROMISE-2. Headache 61(S1):123","journal-title":"Headache"},{"issue":"5","key":"1360_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J, The Triptan Cardiovascular Safety Expert Panel (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44(5):414\u2013425. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04078.x","journal-title":"Headache"},{"issue":"4","key":"1360_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1067\/mcp.2000.110502","volume":"68","author":"JN de Hoon","year":"2000","unstructured":"de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, Van Bortel LM (2000) Vascular effects of 5-HT1B\/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 68(4):418\u2013426. https:\/\/doi.org\/10.1067\/mcp.2000.110502","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01360-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:32:12Z","timestamp":1638297132000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01360-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01360-1","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each study included in this analysis was approved by an institutional review board or independent ethics committee. The studies were registered at  under , , , and . In each study, patients provided written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<b>TRS<\/b> has been a consultant and\/or scientific advisor for Alder\/Lundbeck, Amgen, Biohaven, Eli Lilly, Impel Neuropharma, and Theranica, and has received research support from Alder\/Lundbeck, Allergan, Amgen, Biohaven, Charleston Labs, Eli Lilly, electroCore, Novartis, Novo Nordisk, Satsuma, Theranica, and Vorso.<b>ELHS<\/b> received research grants as a clinical trial investigator from Alder BioPharmaceuticals and is also a member of Lundbeck\u2019s Speaker Bureau.<b>RC, AE,<\/b> and <b>VS<\/b> are employees of Lundbeck or one of its subsidiary companies.<b>JH<\/b> is an employee of Pacific Northwest Statistical Consulting, Inc., a contracted service provider of biostatistical resources for H. Lundbeck A\/S.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}